(616 KB)

: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can:

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC (616 KB)

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications : Investigating approaches where patients only take the

: For those who stopped the medication, the median time until they did so was only 7 months . (616 KB)

(616 — Kb)

: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can:

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications

: For those who stopped the medication, the median time until they did so was only 7 months .